PURPOSE: Radiolabelled interleukin-2 is a radiopharmaceutical used for the study of chronic inflammatory processes. (123)I-labelled interleukin-2 has successfully been used in a large number of patients affected by several immune-mediated diseases. (123)I, however, is expensive and not readily available. We have, therefore, developed a method for labelling interleukin-2 with (99m)Tc to high specific activity based on the use of an N(3)S bifunctional chelating agent. In this paper, we describe the results obtained with (99m)Tc-interleukin-2 in a series of eight normal subjects and of 12 patients with autoimmune thyroid diseases. METHODS: Biodistribution, pharmacokinetics, haematological and systemic toxicity, radiation absorbed dose and in vivo targeting were studied. RESULTS: Results showed rapid plasma clearance of (99m)Tc-interleukin-2 with retention mainly in the kidneys. Biodistribution and kinetics were similar to that observed for (123)I-interleukin-2. No acute systemic toxicity was found; a small decrease in peripheral blood lymphocytes was observed in the first hours only in patients, but it was mild and transient. (99m)Tc-interleukin-2 accumulated, to varying extents, in the thyroid of all patients affected by autoimmune thyroid diseases but not in the thyroid of normal subjects. The effective dose equivalent of a diagnostic activity of (99m)Tc-interleukin-2 (185 MBq) was 1.35 mSv. No correlation was observed between thyroid autoantibodies and uptake of (99m)Tc-interleukin-2. CONCLUSIONS: The use of (99m)Tc-interleukin-2 is safe and simple; the favourable dosimetry and biodistribution and the rapid clearance make it potentially useful for the study of chronic inflammatory diseases such as autoimmune thyroid disease.
PURPOSE: Radiolabelled interleukin-2 is a radiopharmaceutical used for the study of chronic inflammatory processes. (123)I-labelled interleukin-2 has successfully been used in a large number of patients affected by several immune-mediated diseases. (123)I, however, is expensive and not readily available. We have, therefore, developed a method for labelling interleukin-2 with (99m)Tc to high specific activity based on the use of an N(3)S bifunctional chelating agent. In this paper, we describe the results obtained with (99m)Tc-interleukin-2 in a series of eight normal subjects and of 12 patients with autoimmune thyroid diseases. METHODS: Biodistribution, pharmacokinetics, haematological and systemic toxicity, radiation absorbed dose and in vivo targeting were studied. RESULTS: Results showed rapid plasma clearance of (99m)Tc-interleukin-2 with retention mainly in the kidneys. Biodistribution and kinetics were similar to that observed for (123)I-interleukin-2. No acute systemic toxicity was found; a small decrease in peripheral blood lymphocytes was observed in the first hours only in patients, but it was mild and transient. (99m)Tc-interleukin-2 accumulated, to varying extents, in the thyroid of all patients affected by autoimmune thyroid diseases but not in the thyroid of normal subjects. The effective dose equivalent of a diagnostic activity of (99m)Tc-interleukin-2 (185 MBq) was 1.35 mSv. No correlation was observed between thyroid autoantibodies and uptake of (99m)Tc-interleukin-2. CONCLUSIONS: The use of (99m)Tc-interleukin-2 is safe and simple; the favourable dosimetry and biodistribution and the rapid clearance make it potentially useful for the study of chronic inflammatory diseases such as autoimmune thyroid disease.
Authors: T Misaki; J Konishi; T Nakashima; Y Iida; K Kasagi; K Endo; T Uchiyama; K Kuma; K Torizuka Journal: Clin Exp Immunol Date: 1985-04 Impact factor: 4.330
Authors: D K McCulloch; L J Klaff; S E Kahn; S L Schoenfeld; C J Greenbaum; R S Mauseth; E A Benson; G T Nepom; L Shewey; J P Palmer Journal: Diabetes Date: 1990-05 Impact factor: 9.461
Authors: P T Postema; E P Krenning; R Wijngaarde; P P Kooy; H Y Oei; W A van den Bosch; J C Reubi; W M Wiersinga; H Hooijkaas; T van der Loos Journal: J Clin Endocrinol Metab Date: 1994-12 Impact factor: 5.958
Authors: Kornelis S M van der Geest; Maria Sandovici; Pieter H Nienhuis; Riemer H J A Slart; Peter Heeringa; Elisabeth Brouwer; William F Jiemy Journal: Front Med (Lausanne) Date: 2022-06-06
Authors: Marta Opalinska; Tomasz Stompor; Dorota Pach; Renata Mikolajczak; Danuta Fedak; Marcin Krzanowski; Tomasz Rakowski; Anna Sowa-Staszczak; Boguslaw Glowa; Piotr Garnuszek; Michał Maurin; Urszula Karczmarczyk; Władysław Sulowicz; Alicja Hubalewska-Dydejczyk Journal: Eur J Nucl Med Mol Imaging Date: 2012-01-12 Impact factor: 9.236
Authors: Svetomir N Markovic; Filippo Galli; Vera J Suman; Wendy K Nevala; Andrew M Paulsen; Joseph C Hung; Denise N Gansen; Lori A Erickson; Paolo Marchetti; Gregory A Wiseman; Alberto Signore Journal: Oncotarget Date: 2018-07-13